19.6 C
New York
Friday, November 20, 2026

FDA approves vepdegestrant NDA for ESR1-mutated breast cancer


FDA accepts vepdegestrant NDA for ESR1-mutated breast cancer

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles